Pharmaceutical

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

Retrieved on: 
Tuesday, January 10, 2023

NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.

Key Points: 
  • NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.
  • The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.
  • Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD.
  • As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors.

OrganaBio Launches New Website

Retrieved on: 
Monday, January 9, 2023

OrganaBio, LLC launches a brand-new website at www.organabio.com .

Key Points: 
  • OrganaBio, LLC launches a brand-new website at www.organabio.com .
  • The new website expounds on OrganaBio’s mission to empower and strengthen customers’ people, processes, and products on their journey to commercialization and embraces the colorful culture of OrganaBio’s headquarters in Miami.
  • View the full release here: https://www.businesswire.com/news/home/20230109005793/en/
    Attending Phacilitate at Advanced Therapies Week in Miami between January 17-20?
  • Products are offered “off-the-shelf”, ready to ship for preclinical research and in custom and cGMP-compliant formats for clinical development and manufacturing.

LinKinVax Just Completed a New Round of Financing, Initiated in 2022, for a Total of €7,3 M 

Retrieved on: 
Monday, January 9, 2023

LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.

Key Points: 
  • LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.
  • It is predicated on work by the Vaccine Research Institute/Inserm (VRI) in which Inserm, University of Paris Est Créteil (UPEC), and the Mondor Institute of Biomedical Research (IMRB) participate.
  • Englehart, Director, IQT International Ltd UK: “We are impressed by LinKinVax’s team and its vision for developing world-class vaccine technology.
  • This new financing, completed in December 2022, includes a seed funding from private shareholders, beginning of 2022.

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease

Retrieved on: 
Monday, January 9, 2023

We have shared these updates with the FDA as part of our pivotal Phase 2 study design discussions.

Key Points: 
  • We have shared these updates with the FDA as part of our pivotal Phase 2 study design discussions.
  • “Lastly, I am pleased to note an extension of our cash runway, which we expect to fund operations through 2024.
  • Available treatments fail to address the underlying genetics and disease biology and do not alter disease progression.
  • A live audio webcast of the presentation is available under “Events” in the Investors section of the Company’s website at https://ir.rocketpharma.com .

The Corporate Reputation of Pharma Companies in Canada, 2021-2022: The Patient Perspective - The Views of 124 Patient Groups - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Canada Edition - The Views of 124 Canadian Patient Groups" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Canada Edition - The Views of 124 Canadian Patient Groups" report has been added to ResearchAndMarkets.com's offering.
  • Patient groups responding to the 'Corporate Reputation of Pharma' survey are uniquely positioned to comment on the pharma industry's performance during the pandemic.
  • The 124 Canadian patient groups responding to the 2021 'Corporate Reputation' survey rated the pharma industry more favourably for corporate reputation than their predecessors in previous years.
  • 66% of 2021's respondent Canadian patient groups stated that the industry had an "Excellent" or "Good" corporate reputation, against 44% saying the same in 2020.

Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective - The Views of 240 Patient Groups - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - USA Edition - The Views of 240 USA Patient Groups" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - USA Edition - The Views of 240 USA Patient Groups" report has been added to ResearchAndMarkets.com's offering.
  • Patient groups responding to the 'Corporate Reputation of Pharma' survey are uniquely positioned to comment on the pharma industry's performance during the pandemic.
  • The report provides highlights on:
    The 240 US patient groups responding to the 2021 survey rated the pharma industry more favourably for corporate reputation than their predecessors in previous years.
  • 2021's 240 respondent US patient groups registered significant drops in their approval ratings when asked in the 'Corporate Reputation' survey about specific pharma activities of importance to patients and patient groups - especially patient safety, patient centricity, patient information, and integrity.

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Retrieved on: 
Monday, January 9, 2023

ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.

Key Points: 
  • ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.
  • We have fully met our patient enrollment goals in 2022 and are involving new countries and hospitals in 2023.
  • We look forward to continuing the clinical development of glenzocimab in the treatment of myocardial infarction in partnership with the University of Birmingham (UK).
  • The recognition of this pivotal study design supports a future application for marketing authorization for glenzocimab in stroke in Europe.

Corporate Reputation of Global Pharma Companies, 2021-2022: Get The Patient Perspective from 2,150 Patient Groups - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Global Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Global Edition" report has been added to ResearchAndMarkets.com's offering.
  • The 'Corporate Reputation of Pharma' survey is now in its 11th year, and two years into the Covid-19 pandemic.
  • Patient groups responding to 2021's 'Corporate Reputation of Pharma' survey are uniquely positioned to comment on the pharma industry's performance during the pandemic.
  • Continue reading for details on:
    How the analyst measures pharma's corporate reputation from a patient perspective;
    The headline results of the 2021 Global survey;
    The companies included in the 2021 analysis; and
    The profiles of 2021's respondent patient groups.

Patient Perspective of the Corporate Reputation of Pharma in 2021-2022: The Views of 121 Respiratory Conditions Patient Groups - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Respiratory Edition - The Views of 121 Respiratory Conditions Patient Groups" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Respiratory Edition - The Views of 121 Respiratory Conditions Patient Groups" report has been added to ResearchAndMarkets.com's offering.
  • Patient groups- and respiratory-conditions patient groups especially possess a deep and unique understanding of the patients they represent and express the collated views of these patients.
  • The report provides details on:
    How the analyst measures pharma's corporate reputation from a patient perspective;
    The companies included in the 2021 respiratory-conditions analysis;
    The headline results of the 2021 survey, from the perspective of respiratory-conditions patient groups; and
    The profiles of 2021's respondent respiratory-conditions patient groups.
  • Relationships that respondent respiratory-conditions patient groups have with pharma, 2021
    Industry-wide findings for respiratory conditions, 2021
    Rankings of 16 pharma companies, 2021 v. 2020, as assessed by respondent respiratory-conditions patient groups familiar with the companies
    Rankings of 10 pharma companies, 2021 v. 2020, as assessed by respondent respiratory-conditions patient groups working with the companies
    Rankings of 10 'big-pharma' companies, 2021 v. 2020, as assessed by respondent respiratory-conditions patient groups familiar with the companies
    Rankings of 8 'big-pharma' companies, 2021 v. 2020, as assessed by respondent respiratory-conditions patient groups working with the companies
    Profiles of the 16 companies, 2021 (v. 2020)
    I. Profiles of respondent respiratory-conditions patient groups, 2021
    II.

Global Controlled Release Drug Delivery Market Research Report 2022: Drug Dosage Analysis, Price and Clinical Trial Insights to 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The "Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2028" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2028" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The search for innovative solutions to the problems associated with the delivery of drugs ended with the arrival of the controlled-release drug market in the pharmaceutical sector.
  • In the past few years, the novel and mechanistic approach followed by the controlled release drugs in the treatment regimen has brought great appreciation in the pharmaceutical industry.
  • The efforts involved in the development of the market and associated parameters have helped the market to deliver promising results, thus, making the controlled release mechanism one of the widely accepted and appreciated drug delivery systems.